These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34368325)

  • 1. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report.
    Ding XS; Mi L; Song YQ; Liu WP; Yu H; Lin NJ; Zhu J
    World J Clin Cases; 2021 Jul; 9(21):6041-6048. PubMed ID: 34368325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
    Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
    Wang C; Liu Y; Dong L; Li X; Yang Q; Brock MV; Mei Q; Liu J; Chen M; Shi F; Liu M; Nie J; Han W
    Clin Cancer Res; 2021 May; 27(10):2782-2791. PubMed ID: 33674274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tislelizumab for the treatment of classical Hodgkin's lymphoma.
    Chen J; Zhang H; Zhu L; Zhao Y; Ding Y; Yuan Y
    Drugs Today (Barc); 2020 Dec; 56(12):781-785. PubMed ID: 33332484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.
    Yan Z; Ma J; Yao S; Yao Z; Wang H; Chu J; Zhao S; Liu Y
    Front Immunol; 2021; 12():727464. PubMed ID: 34899689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
    Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Yang L; Elstrom R; Huang J; Novotny W; Wei V; Zhu J
    Leukemia; 2020 Feb; 34(2):533-542. PubMed ID: 31520078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Tarekegn K; Colon Ramos A; Singh B; Sequeira Gross HG; Gupta S
    World J Oncol; 2021 Aug; 12(4):81-84. PubMed ID: 34349851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
    Vardhana S; Cicero K; Velez MJ; Moskowitz CH
    Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
    Han X; Liu X; Zhang C; Wen Q; Zhang X
    J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sintilimab as salvage treatment in an HIV patient with relapsed/refractory Hodgkin: a case report.
    Shi Y; Li Q; Zhang W; Nan Y; Yang T; Liang X; Xiao C; Guo B; Xiang Y
    Ann Palliat Med; 2020 Jul; 9(4):2414-2419. PubMed ID: 32692239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
    Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Zhao X; Wang D; Zhang P; Wang Y; Wang L; Liu T; Zhang Y; Shen Z; Huang J; Zhu J
    Clin Cancer Res; 2022 Mar; 28(6):1147-1156. PubMed ID: 34716199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma.
    Nie J; Wang C; Zheng L; Liu Y; Wang C; Chang Y; Hu Y; Guo B; Pan Y; Yang Q; Hu X; Han W
    Blood; 2024 Aug; ():. PubMed ID: 39093981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Bekoz H; Ozbalak M; Karadurmus N; Paydas S; Turker A; Toptas T; Tuglular TF; Altuntas F; Cakar MK; Sonmez M; Gulbas Z; Demir N; Kaynar L; Yildirim R; Karadogan I; Arat M; Kapucu I; Aslan NA; Ozkocaman V; Turgut M; Yuksel MK; Ozcan M; Hacioglu SK; Barista I; Demirkaya M; Saydam G; Toprak SK; Yilmaz M; Demirkol O; Ferhanoglu B
    Ann Hematol; 2020 Nov; 99(11):2565-2576. PubMed ID: 32507911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report.
    Li LJ; Zhang JY
    World J Clin Cases; 2022 Oct; 10(28):10193-10200. PubMed ID: 36246799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine-plus-camrelizumab epi-immunotherapy and treatment cessation.
    Wang C; Pan Y; Liu Y; Guo B; Shi J; Rong G; Guo Z; Li Z; Yang Q; Nie J; Han W
    MedComm (2020); 2023 Dec; 4(6):e428. PubMed ID: 38020717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Checkpoint inhibitors in Hodgkin lymphoma].
    Sasse S; Momotow J; Engert A
    Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.